FIELD: chemistry.
SUBSTANCE: invention relates to 1.7-diazacarbazole compounds of formula (I) or to its solvates, hydrates or salts , where X, Y, Z, R3, R5 and R6 are such as given in i.1 of the invention formula. In addition, invention relates to pharmaceutical composition, containing formula (I) compounds, which possesses inhibiting activity with respect to kinase of control point 1 (chk1).
EFFECT: novel compounds, which can be useful as kinase inhibitors and therefore are useful as anticancer therapeutic medications, are obtained and described.
26 cl, 403 ex, 16 tbl
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVE 6-CARBONITRILE DIPYRIDOPYRROLES AND APPLICATION THEREOF IN CANCER TREATMENT | 2010 |
|
RU2575635C2 |
SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | 2013 |
|
RU2666538C2 |
TRICYCLIC PYRROLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF AS KINASE INHIBITORS | 2012 |
|
RU2591191C2 |
PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | 2014 |
|
RU2663898C2 |
HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | 2012 |
|
RU2648997C2 |
HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
MODULATORS OF NUCLEAR RECEPTORS | 2016 |
|
RU2715897C2 |
POLYCYCLIC ANTAGONISTS OF TLR7/8 AND THEIR USE IN TREATMENT OF IMMUNE DISORDERS | 2016 |
|
RU2783748C2 |
Authors
Dates
2014-05-20—Published
2009-06-10—Filed